Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its self-developed mRNA Mpox vaccine. The candidate becomes China’s first and the world’s third mRNA Mpox vaccine to receive U.S. regulatory clearance for clinical trials, positioning the company to address unmet needs in immunocompromised patient populations.
Regulatory Milestone
Item
Detail
Agency
U.S. Food and Drug Administration (FDA)
Approval Type
IND clearance (Phase I-ready)
Product
Investigational mRNA Mpox vaccine
Developer
Ab&B Bio-Tech CO., LTD. JS (HKG: 2627)
Significance
China’s 1st; World’s 3rd mRNA Mpox vaccine with FDA IND
Approval Date
4 Mar 2026
Next Steps
Phase I clinical trial initiation in U.S.
Preclinical Evidence
Parameter
mRNA Candidate
Comparator (Tiantan Strain)
Advantage
Mpox Neutralizing Antibodies
Significantly higher levels
Live-attenuated vaccinia virus
Superior immunogenicity
Cross-Reactivity
Broad-spectrum against multiple orthopoxvirus antigens
Limited
Enhanced protection spectrum
Safety Profile
Replication-deficient mRNA platform
Replication-competent live virus
Suitable for immunocompromised
Mechanism: mRNA-encoded orthopoxvirus antigens eliciting humoral and cellular immunity
Differentiation: Non-replicating platform eliminates risk of systemic vaccinia infection in immunodeficient hosts
Competitive Positioning & Market Opportunity
Factor
Strategic Implication
Target Population
HIV-positive individuals and other immunocompromised patients contraindicated for live vaccines
Global Supply Gap
Current licensed Mpox vaccines (JYNNEOS, ACAM2000) have immunogenicity limitations in HIV populations
Market Entry
Potential first-mover advantage in mRNA Mpox segment for high-risk demographics
Manufacturing
mRNA platform enables rapid scale-up and variant-adaptable formulation
Clinical Development: Phase I trial design expected to include HIV-positive cohorts to demonstrate safety/immunogenicity in target population
Regulatory Strategy: Parallel China NMPA filing anticipated; potential for FDA Breakthrough Therapy designation given unmet need
Strategic Outlook
Valuation Impact: IND approval validates Ab&B’s mRNA platform technology; shares (HKG: 2627) expected to react positively
Partnership Potential: Multinational vaccine manufacturers may seek co-development/commercialization rights for ex-China markets
Pipeline Expansion: Platform applicability to other orthopoxviruses (smallpox, cowpox) and hemorrhagic fever viruses
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and commercial potential for Ab&B Bio-Tech’s mRNA Mpox vaccine. Actual results may differ due to trial outcomes, manufacturing capabilities, and competitive dynamics in the infectious disease vaccine market.-Fineline Info & Tech
By Fineline Cube